JP2022513517A5 - - Google Patents
Info
- Publication number
- JP2022513517A5 JP2022513517A5 JP2021535249A JP2021535249A JP2022513517A5 JP 2022513517 A5 JP2022513517 A5 JP 2022513517A5 JP 2021535249 A JP2021535249 A JP 2021535249A JP 2021535249 A JP2021535249 A JP 2021535249A JP 2022513517 A5 JP2022513517 A5 JP 2022513517A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- carcinoma
- group
- squamous cell
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306783.4A EP3669874A1 (en) | 2018-12-20 | 2018-12-20 | Quinoline derivatives for use in the treatment or prevention of cancer |
| EP18306783.4 | 2018-12-20 | ||
| PCT/EP2019/086470 WO2020127839A1 (en) | 2018-12-20 | 2019-12-19 | Quinoline derivatives for use in the treatment or prevention of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513517A JP2022513517A (ja) | 2022-02-08 |
| JP2022513517A5 true JP2022513517A5 (cg-RX-API-DMAC10.html) | 2023-01-31 |
| JP7570641B2 JP7570641B2 (ja) | 2024-10-22 |
Family
ID=65200518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535249A Active JP7570641B2 (ja) | 2018-12-20 | 2019-12-19 | 癌の処置又は予防において使用する為のキノリン誘導体 |
Country Status (11)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| TW202436296A (zh) * | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物晶型及其製備方法 |
| WO2025027388A1 (en) | 2023-08-01 | 2025-02-06 | Abivax | Obefazimod for treatment of ulcerative colitis |
| IL326865A (en) * | 2023-08-30 | 2026-04-01 | Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd | Compound for regulating activity of microrna-124 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102625804B (zh) | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CN103787992B (zh) * | 2014-01-21 | 2016-04-20 | 华东理工大学 | N,n-双取代苯并氮杂环-2-胺类化合物及其用途 |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP3059236A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| JP6474334B2 (ja) * | 2015-07-30 | 2019-02-27 | 株式会社キーエンス | 画像検査装置、画像検査方法および画像検査プログラム |
| WO2017158201A1 (en) * | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
-
2018
- 2018-12-20 EP EP18306783.4A patent/EP3669874A1/en not_active Withdrawn
-
2019
- 2019-12-19 WO PCT/EP2019/086470 patent/WO2020127839A1/en not_active Ceased
- 2019-12-19 MA MA054512A patent/MA54512A/fr unknown
- 2019-12-19 MX MX2021007178A patent/MX2021007178A/es unknown
- 2019-12-19 CN CN201980088810.8A patent/CN113543784A/zh active Pending
- 2019-12-19 KR KR1020217022546A patent/KR20210136969A/ko not_active Ceased
- 2019-12-19 KR KR1020257024660A patent/KR20250117703A/ko active Pending
- 2019-12-19 EP EP19829187.4A patent/EP3897639A1/en active Pending
- 2019-12-19 CN CN202411117196.2A patent/CN118986981A/zh active Pending
- 2019-12-19 US US17/416,679 patent/US20220071985A1/en active Pending
- 2019-12-19 IL IL284124A patent/IL284124B2/en unknown
- 2019-12-19 BR BR112021012132-3A patent/BR112021012132A2/pt unknown
- 2019-12-19 AU AU2019408244A patent/AU2019408244B2/en active Active
- 2019-12-19 JP JP2021535249A patent/JP7570641B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517616A5 (cg-RX-API-DMAC10.html) | ||
| JP2020514419A5 (cg-RX-API-DMAC10.html) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2020508302A5 (cg-RX-API-DMAC10.html) | ||
| AU2011302344B2 (en) | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients | |
| JP2020515578A5 (cg-RX-API-DMAC10.html) | ||
| JP2022507020A5 (cg-RX-API-DMAC10.html) | ||
| ES2528167T3 (es) | Tratamiento de tumores usando anticuerpo anti-L1, específico. | |
| CN120285177A (zh) | Hdac抑制剂和pd-1抑制剂的组合疗法 | |
| BR112020003646A2 (pt) | cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal. | |
| JP2017186337A5 (cg-RX-API-DMAC10.html) | ||
| PT2552959T (pt) | Anticorpos para muc16 e métodos de utilização dos mesmos | |
| JP2020518669A5 (cg-RX-API-DMAC10.html) | ||
| JP2021522249A5 (cg-RX-API-DMAC10.html) | ||
| TWI462908B (zh) | 用於治療增生性失調症的化合物 | |
| CN101801983A (zh) | 调控hsp90活性的三唑化合物 | |
| JP2019529518A5 (cg-RX-API-DMAC10.html) | ||
| JP2014193925A5 (cg-RX-API-DMAC10.html) | ||
| JP2012505916A5 (cg-RX-API-DMAC10.html) | ||
| JP2014528464A5 (cg-RX-API-DMAC10.html) | ||
| JP2020534300A5 (cg-RX-API-DMAC10.html) | ||
| RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты | |
| KR20260061205A (ko) | Kras 억제제 및 이의 용도 | |
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2022512401A5 (cg-RX-API-DMAC10.html) |